Free educational webinar hosted by Hardy Diagnostics offered with continuing education credits
SANTA MARIA, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) — Carbapenemase-resistant Enterobacterales (CRE) are a major concern for patients in health care facilities. Some bacteria in this family are resistant to nearly all antibiotics, leaving only more toxic or less effective treatment options.
To learn more about the utility of screening for Carbapenem-resistant Enterobacterales and the technologies that are available to do so, Hardy Diagnostics is pleased to offer a free webinar titled, “Detection of carbapenemase-producing organisms; advancements and barriers to the clinical lab,” on Oct. 7, 2021, at 11 a.m. PST/1 p.m. CST.
Led by Nathan Ledeboer, PhD, D(ABMM), F(AAM) this discussion will:
Dr. Nathan Ledeboer is a Professor and Vice Chair of Pathology at the Medical College of Wisconsin, and Medical Director of Microbiology, Molecular Diagnostics, reference services, and laboratory client services at Froedtert Hospital and Wisconsin Diagnostic Laboratories. He is also the editor of the Journal of Clinical Microbiology.
This free webinar is presented by Hardy Diagnostics.
C.E. credits are offered in partnership through the Northern California Branch of the American Society of Microbiology (NCASM) LFS #400.
Click here to register for this educational webinar. For more information, contact Megan Roesner at roesnerm@hardydiagnostics.com.
To learn more about the products offered at Hardy Diagnostics to detect and diagnose disease, please visit www.hardydiagnostics.com.
Related Images
This content was issued through the press release distribution service at Newswire.com.
Attachment
SINGAPORE, April 12, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (“MNDR” or “the Company”), a…
Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst…
SAN FRANCISCO, April 12, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS)…
Gross Margin Improved 300 basis points to 31% Year-Over-Year Adjusted EBITDA Grew 30% Year-Over-Year EPS…
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link…
This conclusion is the result of almost 10 years of research carried out by the…